BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol 2020;55:1146-56. [PMID: 32780604 DOI: 10.1080/00365521.2020.1803396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Molinero N, Taladrid D, Zorraquín-peña I, de Celis M, Belda I, Mira A, Bartolomé B, Moreno-arribas MV. Ulcerative Colitis Seems to Imply Oral Microbiome Dysbiosis. CIMB 2022;44:1513-27. [DOI: 10.3390/cimb44040103] [Reference Citation Analysis]
2 Fukushima S, Shiotani A, Matsumoto H, Handa O, Handa Y, Osawa M, Murao T, Umegaki E, Kawano M, Inoue R, Naito Y. Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-41] [Reference Citation Analysis]
3 Wang Y, Wu G, Zhao L, Wang W, Cooper VS. Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome. mBio. [DOI: 10.1128/mbio.03801-21] [Reference Citation Analysis]
4 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
5 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Reference Citation Analysis]
6 Bakir-gungor B, Hacılar H, Jabeer A, Nalbantoglu OU, Aran O, Yousef M. Inflammatory bowel disease biomarkers of human gut microbiota selected via different feature selection methods. PeerJ 2022;10:e13205. [DOI: 10.7717/peerj.13205] [Reference Citation Analysis]
7 Öhman L, Lasson A, Strömbeck A, Isaksson S, Hesselmar M, Simrén M, Strid H, Magnusson MK. Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. Sci Rep 2021;11:8641. [PMID: 33883600 DOI: 10.1038/s41598-021-87973-7] [Reference Citation Analysis]
8 Adamkova P, Hradicka P, Gancarcikova S, Kassayova M, Ambro L, Bertkova I, Maronek M, Farkasova Iannaccone S, Demeckova V. Single Donor FMT Reverses Microbial/Immune Dysbiosis and Induces Clinical Remission in a Rat Model of Acute Colitis. Pathogens 2021;10:152. [PMID: 33540919 DOI: 10.3390/pathogens10020152] [Reference Citation Analysis]
9 Aldars-García L, Chaparro M, Gisbert JP. Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms 2021;9:977. [PMID: 33946482 DOI: 10.3390/microorganisms9050977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]